AzTrials
AzTrials

Cutaneous T-Cell LymphomaPhase 4NCT06285370

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

A Phase 4 study testing Mogamulizumab in people with Cutaneous T-Cell Lymphoma, run by Kyowa Kirin China Pharmaceutical Co., Ltd. at 8 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cutaneous T-Cell Lymphoma
What is being tested?
Mogamulizumab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
8 sitesChina
Study dates
29 May 2023to 10 Nov 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Voluntarily signed and dated ethics committee (EC) approved informed consent form in accordance with regulatory and institutional guidelines. Written informed consent must be obtained prior to performing any study-related procedure.
  • Male and female Chinese subjects ≥18 years of age at the time that written informed consent is obtained.
  • Histologically confirmed diagnosis of MF or SS;
  • Stage IB, IIA, IIB, III, and IV.
  • Patients who have failed at least one prior systemic therapy. Systemic therapy includes, for example, interferon, denileukin diftitox, retinoid, photopheresis, anti-neoplastic chemotherapy, methotrexate, and Histone deacetylase (HDAC) inhibitor.
  • Ultraviolet light therapy (Psoralen plus ultraviolet A [PUVA], ultraviolet B [UVB] etc), systemic steroid monotherapy, topical steroid or other topical agents, and any radiation are not considered to be a systemic therapy.
Show all 21Show fewer
  • Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1.
  • The subject has resolution of all clinically significant toxic effects of prior cancer therapy to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE, ver. 5.0) excluding the specifications required in 8, 9, and 10 below.
  • Adequate hematological function:
  • absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L;
  • platelets ≥ 100.0 × 10^9/L;
  • in subjects with known bone marrow involvement, ANC must be ≥ 1.0 × 10^9/L and platelets ≥ 75.0 × 10^9/L.
  • Adequate hepatic function:
  • Total bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN);
  • aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 × ULN or ≤ 5.0 × ULN in the presence of known hepatic involvement by CTCL.
  • Adequate renal function:
  • serum creatinine (SCr) ≤ 1.5 × ULN, or calculated creatinine clearance (CCr)> 50 mL/min using the Cockcroft-Gault formula. To calculate CCr, the body weight and SCr results on the same day should be used.
  • Patients with MF and a known history of non-complicated staphylococcus infection/colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics.
  • Women of childbearing potential must have a negative pregnancy test within 7 days prior to receiving study medication.
  • Women of childbearing potential (WOCBP)* and fertile men who consent to practice contraception using highly effective methods during a period from the day providing her consent to the end of the study (for women) or from the start of IP administration to the end of the study (for men). WOCBP shall have a negative pregnancy test result in the screening examination and a negative pregnancy test result in the pre-dose examination at Day 1.
  • WOCBP do not include women who underwent permanent contraception, postmenopausal women (in the case of the absence of menstruation for 12 months or more regardless of other medical reasons and serum follicle stimulating hormone (FSH) level >40 mIU/mL) and women who are anatomically incapable of becoming pregnant.

Who cannot join

  • Current evidence of large cell transformation (LCT). Patients with clinical features suggestive of LCT are recommended to have a biopsy performed within 4 months prior to Cycle 1 Day 1 to rule out transformed disease. Patients with a history of LCT but without current aggressive disease and no current evidence of LCT on pathology in skin or lymph nodes are eligible.
  • Diagnosed with a malignancy other than MF/SS in the past 2 years from the time that written informed consent is obtained. However, subjects with non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current prostate-specific antigen of < 0.1 ng/mL, treated thyroid cancer or cervical carcinoma in situ, or ductal/lobular carcinoma in situ of the breast within the past 2 years may be enrolled as long as there is no current evidence of disease.
  • Clinical evidence of central nervous system metastasis.
  • Psychiatric illness, disability or social situation that would compromise the subject's safety or ability to provide consent, or limit compliance with study requirements.
  • Significant uncontrolled intercurrent illness including, but not limited to:
  • uncontrolled infection requiring antibiotics;
Show all 27Show fewer
  • clinically significant cardiac disease (Class III or IV of the New York Heart Association [NYHA] classification);
  • unstable angina pectoris;
  • angioplasty, stenting, or myocardial infarction within 6 months;
  • uncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg or diastolic BP>100 mmHg, found on 2 consecutive measurements separated by a 1-week period) despite 2 antihypertensive medications;
  • clinically significant cardiac arrhythmia;
  • uncontrolled diabetes.
  • Known or tests positive for human immunodeficiency virus (HIV) or history of HIV infection, or hepatitis C disease or history of hepatitis C infection.
  • Tests positive for hepatitis B virus surface (HBs) antigen or both HBc antibody and hepatitis B virus (HBV)-DNA positive (over the lower limit of quantification);
  • Patients with HBs antibody positive due to a hepatitis B vaccine will be allowed to participate in this trial.
  • Active herpes simplex or herpes zoster. Patients on prophylaxis for herpes who started taking medication at least 30 days prior to the pretreatment visit, have no signs of active infection, and whose last active infection was more than 6 months ago may enter the study, and should continue to take the prescribed medication for the duration of the study.
  • Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins.
  • Known active autoimmune disease (e.g., Graves' disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease; psoriasis).
  • Is pregnant (confirmed by beta human chorionic gonadotrophin [β-HCG]) or lactating.
  • Prior treatment with mogamulizumab.
  • Have had any therapy directed against the subject's underlying cancer or any investigational medications within 4 weeks of registration (skin directed treatments, including topicals and radiation within 2 weeks of registration treatment).
  • Subjects on a stable dose of a low dose systemic corticosteroid (≤ 20 mg prednisone equivalent) for at least 4 weeks prior to the registration may continue use although the investigator should attempt to taper the use to the lowest dosage tolerable while on study.
  • Subjects on a stable dose of medium or low potency topical corticosteroids for at least 4 weeks prior to the registration may continue use at the same dose, although the investigator should attempt to taper the use to the lowest dosage tolerable while on study.
  • History of allogeneic transplant.
  • Autologous hematopoietic stem cell transplant within 90 days of the screening.
  • Patients on any immunomodulatory drug for concomitant or intercurrent conditions or who have received any of these agents within 4 weeks of registration, including but not limited to the following, will be excluded: low-dose or oral methotrexate, azathioprine, iv immunoglobulin, low-dose or oral cyclophosphamide, cyclosporine, mycophenolate, infliximab, etanercept, leflunomide, adalimumab, lenalidomide, abatacept, rituximab, anakinra, interferon-β, interleukin-2, and natalizumab.
  • Anyone otherwise considered unsuitable participation in the study by the investigator or subinvestigator.

Trial locations and contacts

8 sites in 1 country.

8 sites in 1 country

China8 sites

  • Peking University First Hospital, Department of Dermatology and Venereology

    Beijing, Beijing Municipality, 100034

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610044

  • Sun Yat-sen University Cancer Center, Department of Medical Oncology

    Guangzhou, Guangdong, 510060

  • ZheJiang Cancer Hospital

    Hangzhou, Zhejiang, 310005

  • First Affiliated Hospital of Zhengzhou University

    Henan, Zhengzhou, 450052

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, 010000

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110002

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei

Other trials in China

About this study

Official title: An Open-Label, Multicenter, Single Arm Study to Evaluate the Efficacy and Safety of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy

Read the detailed description

This is an open-label, multicenter, single arm study. This study consists of three parts: the Pretreatment Period, the Treatment Period, and the Follow-up Period. Subjects who meet all of eligibility criteria by the screening examination will be enrolled into the study, and start treatment with mogamulizumab within 30 days after obtaining consent. Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met. After stopping treatment, the end-of treatment examination will be conducted within 30 days after the last dose.The primary efficacy analysis will be conducted once all subjects terminate treatment by the confirmation of PD/drug intolerance/unacceptable toxicity or 12 months after the date of the first mogamulizumab administration of the last subject of entire study, whichever comes first.

Being tested
Mogamulizumab
Keywords
mycosis fungoides/sézary syndrome
Medical subject headings
Lymphoma, T-Cell, Cutaneous

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MogamulizumabDrug

    Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.

Study groups in NCT06285370
Study groupRoleWhat they receive
KW-0761ExperimentalPatients will receive KW-0761 in this arm
Receives: Drug: Mogamulizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Response Rate

    The ORR was defined as the count of subjects who had a confirmed CR or PR, defined as documented CR or PR per Global Composite Response Score that was confirmed by a subsequent observation at least 4 weeks later. Overall Response Rate was determined based on the response in all compartments (lymph nodes, skin, peripheral blood, and viscera), referencing Olsen, 2011 as follows: Complete Response (CR) = complete disappearance of all clinical evidence of disease; Partial Response (PR) = regression of measurable disease; Stable Disease (SD) = failure to attain CR, PR, or PD; Progressive Disease (PD) = PD in any compartment; Relapse = recurrence of disease in prior CR in any compartment.

    Measured: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

Secondary outcomes (9)

  1. Skin disease response rate;

    Skin disease will be evaluated using the modified SWAT. The detailed response criteria (CR, PR, PD, SD) is defined in Olsen 2011. Complete response (CR) or partial response (PR) will be regarded as response. Response rate is calculated by Subjects who confirmed response/Total subjects

    Measured: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

  2. Lymth nodes response rate

    Lymph nodes status will be evaluated by enhanced computed tomography (CT）. The detailed response criteria (CR, PR, PD, SD) is defined in Olsen 2011. Complete response (CR) or partial response (PR) will be regarded as response. Response rate is calculated by Subjects who confirmed response/Total subjects

    Measured: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

  3. Visceral metastases response rate;

    Visceral disease status will be evaluated by enhanced computed tomography (CT）. The detailed response criteria (CR, PR, PD, SD) is defined in Olsen 2011. Complete response (CR) or partial response (PR) will be regarded as response. Response rate is calculated by Subjects who confirmed response/Total subjects.

    Measured: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

  4. Blood disease response rate;

    The response in blood will be assessed by flow cytometry. The detailed response criteria (CR, PR, PD, SD) is defined in Olsen 2011. Complete response (CR) or partial response (PR) will be regarded as response. Response rate is calculated by Subjects who confirmed response/Total subjects.

    Measured: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

  5. Progression Free Survival

    PFS is defined as the time from the first day of a treatment until documented progression or death.

    Progression was defined based on Olsen (2011).

    Measured: Up to 32 months.

  6. Duration of response (DOR)

    The DOR is defined as the time from the date that criteria for CR or PR are met (whichever is first recorded) until the first date that PD or death is objectively documented. Subjects who still continue response at the time of analysis will be censored at the day of their last tumor assessment (from any compartment).

    Measured: Up to 32 months.

  7. Time to response (TTR)

    TTR is defined as the time from the date of first dose to the date that criteria for CR or PR are met (whichever is first recorded). Subjects who do not meet response criteria will be censored at the day of their last tumor assessment (from any compartment).

    Measured: Up to 29 months.

  8. Response rate of lymph node evaluated by Lugano 2014.

    Subjects will be evaluated for response in lymph node based on Lugano 2014 criteria. Disease status will be evaluated by enhanced computed tomography (CT）. The detailed response criteria (CR, PR, PD, SD) is defined in Lugano 2014. Complete response (CR) or partial response (PR) will be regarded as response. Response rate is calculated by Subjects who confirmed response/Total subjects.

    Measured: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

  9. Response rate of viscera evaluated by Lugano 2014 criteria.

    Subjects will be evaluated for response in viscera based on Lugano 2014 criteria. Disease status will be evaluated by enhanced computed tomography (CT）. The detailed response criteria (CR, PR, PD, SD) is defined in Lugano 2014. Complete response (CR) or partial response (PR) will be regarded as response. Response rate is calculated by Subjects who confirmed response/Total subjects.

    Measured: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Feb 2024
  2. Study start29 May 2023
  3. Primary completion12 Aug 2025
  4. Study completion10 Nov 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
This is an open-label, multicenter, single arm study.
Masking
None (open label)
Enrolment
23 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06285370
Sponsor's protocol ID
0761-CN001
Other IDs
CTR20230672
Status last verified
Sep 2026
First submitted
16 Aug 2023
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Mogamulizumab in people with Cutaneous T-Cell Lymphoma, run by Kyowa Kirin China Pharmaceutical Co., Ltd. at 8 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Response Rate (time frame: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06285370.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026; AzTrials last refreshed its copy on 7 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in